Navigation Links
Successful Strategies and Innovative Practices for Bringing FDC Products to Market
Date:3/24/2011

CHAPEL HILL, N.C., March 24, 2011 /PRNewswire/ -- The pharmaceutical industry has turned to lifecycle planning as one of the strategies to offset lackluster pipelines and patent loss. Fixed dose combination (FDC) products not only offer an opportunity to extend patent life for branded products but also the chance to offer payers and patients a differentiated product with a therapeutic benefit.

Unfortunately, getting to market quickly with an FDC is more myth than reality. On average, it takes between five and eight years to go from decision-to-develop to launch and costs an average of $80 million, according to a new Best Practices, LLC report. Thus, successful FDC products require thoughtful planning, beginning early in the product development and lifecycle management process.

"If you want either to expand an indication or go to a second generation launch, you've got to think about that right when your initial Phase III is done or shortly after you've launched the product that you're going to be including in that fixed dose," one R&D veteran noted in the report.

To identify a potentially successful FDC it's important to understand that commercial success depends on the product offering a differentiated medical benefit, according to "Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market." Focusing on value and differentiated benefit is a critical lesson learned, according to executives working with FDC products.

Some of the issues addressed in this research include:

- Chief reason for pursuing FDC development

- Measures used to evaluate success

- Years from decision to develop through launch

- Cost of FDC product development Approximate

- Difficulty areas for bringing FDC product to market

- Reasons for partnering with another company to develop FDC product

- Time lapsed f
'/>"/>

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
4. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
8. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
(Date:12/20/2014)... Parker & Sons, Inc. a focused ... experience in contractor services announces reaching a milestone by ... homeowners of Arizona. Parker and Sons is comprised of ... that make customer service the number one priority. The ... started with one service vehicle and has since grown ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... 2014 Energy Textiles is excited ... available. Celliant, the world’s leading responsive textile, can ... , There are a number of benefits to ... oxygenation and balanced body temperature; which can lead ... relief; enhanced athletic performance; and overall wellness. In ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... December 20, 2014 An evening dress is ... a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled ... beautiful dresses in this great shopping platform. Customers can ... the staff's hard work, Discount-Dress.com has been accepted and praised ... faster and easier shopping stage for clients. In order to ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2
... also Establishes New Site Leadership Team at Cambridge ... Continuing the,solidification of its role as the global ... that Andrew D. Skibo has joined the company,as ... a 19-year,veteran of the company, has been promoted ...
... Philadelphia, PA, December 20, 2007 For U.S. veterans ... health functioning are associated with an increased risk of ... of the journal General Hospital Psychiatry. , "Our findings ... for mental health functioning as a risk factor and ...
... tests, so have advanced disease , , THURSDAY, Dec. 20 ... have health insurance are more likely to die because ... so are typically diagnosed with advanced disease, a new ... finding proffers strong evidence that differences in cancer survival ...
... WOODCLIFF LAKE, N.J., Dec. 20 Par,Pharmaceutical Companies, Inc. ... and Exchange Commission (SEC) its Form 10-Q for the ... for this period had been,delayed due to the work ... periods, which were filed earlier this year.,As a result ...
... Exchange Symbol: AKL, MONTREAL, Dec. 20 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation and ... market,conditions, particularly in the small and micro-cap sector, ... initiative. The Company is currently,contemplating other financing options. ...
... Data Show PROMACTA Significantly Raised Platelet Counts and,Lowered ... Treatment of,Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP), ... GSK ; London) today announced the submission ... States Food and Drug Administration,(FDA) for approval to ...
Cached Medicine News:Health News:MedImmune Expands Scientific and Engineering Leadership 2Health News:MedImmune Expands Scientific and Engineering Leadership 3Health News:MedImmune Expands Scientific and Engineering Leadership 4Health News:MedImmune Expands Scientific and Engineering Leadership 5Health News:Mental health linked to amputation risk in diabetic veterans 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 3Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 2Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 3Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 5Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 6Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 7Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 8Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 9Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 10Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 11Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 12Health News:Akela Pharma provides corporate update 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 3Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 4Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 5
Porous foundation 440 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
The cemented hip joint prosthesis system....
The uncemented hip joint prosthesis system...
Medicine Products: